A Case of Chronic Suppurative Otitis Media Associated with Keratoacanthoma - A Rare Presentation
Sumit Sharma1*, Sanyukta Chakravarty2, Ahmad Aseem Nadeem3, Rashmi Nambiar2, Mahesh Mishra2, BP Singh4 and Suvarna Sharma5
1Professor and Head, Mayo Institute of Medical Sciences, Barabanki, Utter Pradesh, India
2Junior Resident Third Year, Assistant Professor, Mayo Institute of Medical Sciences, Barabanki, Utter Pradesh, India
3Associate Professor, Mayo Institute of Medical Sciences, Barabanki, Utter Pradesh, India
4Department of E.N.T, Mayo Institute of Medical Sciences, Barabanki, Utter Pradesh, India
5Intern, KMC, Manipal, India
*Corresponding Author: Sumit Sharma, Department of E.N.T, Professor and Head, Mayo Institute of Medical Sciences, Barabanki, Utter Pradesh, India.
November 15, 2022; Published: December 26, 2022
Keratoacanthoma is usually a rapidly growing benign tumor of the hair follicles, that is, they originate from pilo-sebaceous glands. Its usual presentation is a firm, cone shaped nodule with a central crator and usually affects the middle aged population and the elederly. It may be best viewed as an aborted malignancy that only rarely progresses into invasive SCC. The risk for SCC development is attributes to genotypic, phenotypic, as well as environmental factors. UV Rays is classified by the IARC (International Agency for Research on Cancer) as a class I carcinogen, sufficient for initiation, promotion, and progression AK into squamous carcinogenesis of the skin,14 and is generally the most important environmental risk factor for SCC. Management includes Surgical excision, preferably microscopically controlled surgery (Mohs surgery).Topical therapeutic treatments such as topical imiquimod, topical or intra-lesional 5-fluoruracil, Cryotherapy, and photodynamic therapy for SCC have been reported.
Keywords: Keratoacanthoma; Mohs Surgery; Basal Keratinocytes; SCC. Ss
- Schwartz RA. “Keratoacanthoma”. Journal of the American Academy of Dermatology 30 (1994): 1-19.
- Vidoviæ R and Dobriæ I. “Pseudokanceroze i pseudo - kancerozne hiperplazije”. In: Dobriæ I, et al. Dermato - venerologija. Zagreb: Grafoplast (1994): 387-391.
- Le ver WF. “Pseudocarcinomatosus hyperplasia”. In: Lever WF, Shaumburg-Lever G, eds. Histopathology of the skin. 7th Philadelphia: JB Lippincott Company (1990): 559-560.
- Mackie RM. “Tumours of the skin”. In: Rook A, Wilkinson DS, Ebling FJG, Cham pion RH, Bur ton JL, eds. Text book of dermatology. Oxford: Blackwell Scientific Publications (1987): 2375-2378.
- Schwartz RA. “The keratoacanthoma: a review”. Journal of Surgical Oncology 12 (1979): 305-317.
- Kwa RE., et al. “Biology of cutaneous squamous cell carcinoma”. Journal of the American Academy of Dermatology 26 (1992): 1-26.
- Gra ham JH. “Selected precancerous skin and mucocutaneous lesions”. In: Neoplasms of the skin and malignant melanoma. Chicago: Year Book (1976): 69-121.
- Wick MR., et al. “Histopathologic considerations in the management of the skin cancer”. In: Schwartz RA, ed. Skin cancer recognition and management. New York: Springer-Verlag (1988): 246-275.
- Ratushny V., et al. “From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma”. Journal of Clinical Investigation 2 (2012): 464-472.
- Callen JP., et al. “Actinic keratoses”. Journal of the American Academy of Dermatology4 (1997): 650-653.
- Glogau RG. “The risk of progression to invasive disease”. Journal of the American Academy of Dermatology 42 (2000): 23-24.
- Salasche SJ. “Epidemiology of actinic keratoses and squamous cell carcinoma”. Journal of the American Academy of Dermatology 42 (2000): 4-7.
- Boukamp P. “Non-melanoma skin cancer: what drives tumor development and progression?” Carcinogenesis 10 (2005): 1657-1667.
- IARC Working Group on the Evaluation of Carcinogenic Risks in Humans. Monographs on the evaluation of carcinogenic risks in humans. A review of human carcinogens: radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (2012): 100D.
- Stratigos A., et al. “Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline”. European Journal of Cancer14 (2015): 1989-2007.
- National Comprehensive Cancer Network. NCCN Guidelines Version 1.2016. Squamous Cell Skin Cancer (2016).
- Breuninger H., et al. “Brief S2k guidelines—cutaneous squamous cell carcinoma”. Journal der Deutschen Dermatologischen Gesellschaft 11 (2013): 37-45, 39-47.
- Bonerandi JJ., et al. “Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions”. Journal of the European Academy of Dermatology and Venereology 25 (2011): 1-51.
- Oster-Schmidt C. “Two cases of squamous cell carcinoma treated with topical imiquimod 5%”. Journal of the European Academy of Dermatology and Venereology 1 (2004): 93-95.
- Morse LG., et al. “Treatment of squamous cell carcinoma with intralesional 5-fluorouracil”. Dermatology Surgery11 (2003): 1150-1153; discussion 1153.
- Marmur ES., et al. “A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer”. Dermatology Surgery 30 (2004): 264-271.